These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22487716)

  • 1. [Medicoeconomic data on rare disease drugs: a move towards more transparency?].
    Schwebig A; Duguet C; Ferry A; Bougé C; Fagon JY; Bismuth C; Ramon J
    Presse Med; 2012 May; 41 Suppl 1():S57-64. PubMed ID: 22487716
    [No Abstract]   [Full Text] [Related]  

  • 2. Small biotechs raring to cash in on the orphan disease market.
    Hersher R
    Nat Med; 2012 Mar; 18(3):330-1. PubMed ID: 22395682
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug patent plan gets mixed reviews.
    Butler D
    Nature; 2009 Feb; 457(7233):1064. PubMed ID: 19256077
    [No Abstract]   [Full Text] [Related]  

  • 4. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
    Moran M
    PLoS Med; 2005 Sep; 2(9):e302. PubMed ID: 16138789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orphan economics: the downside of supplyside pharmacology.
    Samson K
    Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
    [No Abstract]   [Full Text] [Related]  

  • 8. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
    Duguet C; Ferry A
    Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
    Darba J
    Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
    [No Abstract]   [Full Text] [Related]  

  • 10. [The challenges of medicoeconomic assessment, benefit for the patient].
    Meyer F
    Presse Med; 2012 May; 41 Suppl 1():S29-31. PubMed ID: 22503292
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [From drug cost to drug price: steps and decisional processes].
    Bruyninckx M; Nourissier C
    Presse Med; 2012 May; 41 Suppl 1():S40-3. PubMed ID: 22487715
    [No Abstract]   [Full Text] [Related]  

  • 13. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 14. Priced out of the UK market.
    Moran N
    Nat Biotechnol; 2008 Feb; 26(2):151-4. PubMed ID: 18259163
    [No Abstract]   [Full Text] [Related]  

  • 15. [High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders].
    de Souza MV; Krug BC; Picon PD; Schwartz IV
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3443-54. PubMed ID: 21120332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No cure, no pay.
    Møldrup C
    BMJ; 2005 May; 330(7502):1262-4. PubMed ID: 15920131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare diseases and effective treatments: are we delivering?
    Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
    Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
    [No Abstract]   [Full Text] [Related]  

  • 18. Rare diseases mean big profits.
    Murphy RM
    Fortune; 2012 Sep; 166(4):24. PubMed ID: 23072062
    [No Abstract]   [Full Text] [Related]  

  • 19. [Can we decrease pharmacy costs?].
    Azagra Ledesma R
    Aten Primaria; 1993 Feb; 11(3):117-8. PubMed ID: 8453001
    [No Abstract]   [Full Text] [Related]  

  • 20. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.